secwatch.observer — SEC 8-K summary
======================================

Issuer:     PAVmed Inc. (PAVM)
CIK:        0001624326
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001493152-26-013477
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PAVmed completes $45M financing, eliminates convertible debt; Q4 net loss $1.8M
-------------------------------------------------------------------------------

- PAVmed completed $30M Series D preferred offering and $15M senior secured note, eliminating all outstanding convertible securities.
- GAAP net loss attributable to common stockholders $1.8M ($2.05 per share diluted); non-GAAP adjusted loss $0.9M ($1.05 per share).
- Lucid Diagnostics recognized $1.5M EsoGuard revenue in Q4 2025, processed 3,664 tests; awarded VA contract for ~9M veterans.
- Veris Health completed EHR integration with OSU James Cancer Hospital; targeting late 2026 FDA submission for implantable monitor.
- PAVmed appointed Joseph Virgilio as CBO of Medical Devices and licensed endoscopic esophageal imaging technology from Duke University.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1624326/000149315226013477/0001493152-26-013477-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1624326/000149315226013477/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-013477

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer